Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Demiurge and AGN: anyone know of Demiurge?

<< Previous

Bullboard Posts

Next >>

Comment by Garhuton Dec 03, 2020 1:07pm

138 Views

Post# 32029291

RE:Demiurge and AGN: anyone know of Demiurge?

Honestly I am putting my trust in Chris. The last interview we watched of him seemed very sincere. They have full enrollme t on their study. Obviously some patients are already completed the 2 weeks of dosage trial and are now in their second 2 weeks of observations. Personally I'm going to ride out the ups and downs on this one. I have no insight on the Demriuge except for they admitted are not perfect in their own predictions.

<< Previous

Bullboard Posts

Next >>

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi